Australian psychiatrists already prescribe psilocybin and MDMA for depression and PTSD

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

How psilocybin could transform mental health treatment

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

Mental health applications of psychedelics

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

Psychedelics interact with neurotransmitter systems to alter one's perception

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

Psychedelic side effects, including worsening mental health for some patients, give pause

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

Psychedelic DMT—part of ayahuasca—shows antidepressant promise in small clinical trial

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

Watch veterans experience psilocybin at a Mexican clinic and discuss the aftermath

This "60 Minutes" episode from 2025 follows nine veterans attending a week-long psychedelic retreat to treat their PTSD. Most of the vets say the experience at the Mexican clinic was life-changing. But results were mixed: One veteran reported he was scared and that the experience worsened his mental health overall.

LSD-like drugs may inspire new antidepressants

LSD and psilocybin have shown promise as antidepressants. Using a virtual library of similar chemical compounds, researchers determined via animal studies that two molecules inspired by LSD have antidepressant effects without any associated hallucinogenic experience. These molecules were found to be 40 times more potent than the common antidepressant fluoxetine, also known as Prozac, with antidepressant effects lasting up to 21 days.

Can microdosing improve mental health?

Animal studies involving microdoses of psilocybin, the psychoactive component in magic mushrooms and ketamine, found it helped to alleviate anxiety and inflammation, an immune response that can cause damage when chronically active. Human studies are ongoing. In at least one double-blind study, where researchers and patients don't know who got a placebo versus the real thing, about half of the participants incorrectly guessed they had been given placebos.

Psychedelic therapy's ethical guidelines (or lack thereof)

With a checkered history of misconduct, how will psychedelic-assisted therapists be held accountable in the emerging legal field? This article explores the nascent field's need for ethical guidelines and clear protection of patient rights when therapeutic breakthroughs teeter "on the edge of consent."

The commercial and therapeutic potential of psychedelics

A 2006 study into the potential therapeutic benefits of psychedelics sparked a renewed interest in the field of psychedelic research, a development that has cascaded into commercialized ventures and experiences. This article details how growing research into the psychological benefits of psychedelics is matched by the rise of anecdotal reports, book deals, businesses, and corporate claims seeking to capitalize on psychedelic potential.

Using psychedelics to manage a cancer diagnosis

Dr. Roland Griffiths helped lead the revival of psychedelic research, often prescribing the use of psilocybin to address severe depression or anxiety in patients. This podcast explores how Griffiths leaned on his own career after being diagnosed with cancer and facing the prospect of death.

How Western psychedelics research fell to the wayside

Psychedelics' modern era began when LSD was discovered in the 1930s. By the 1950s, clinical trials were underway. US user experimentation outside of medical settings (and high-profile violence, like the Manson murders) inspired negative attitudes toward psychedelics, leading to use restrictions that prohibited companies from patenting psychedelic compounds. This strangled psychedelics' profitability until the 1990s when the government loosened its grip and psychedelics research began seeing a resurgence.

Ibogaine, a psychedelic substance, can be used to treat mental illness

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.

Psychedelic drugs are having a scientific renaissance

After decades of repression, psychedelic research is making a resurgence. Hear from a host of experts in this 20-minute video on what that could mean for the future of mental health. The current science on psychedelics believes LSD can cause a particular brain network to quiet or deactivate.

Are psychedelics legal in your state?

The answer is usually more complicated than a simple yes or no. This resource includes a state-by-state and international breakdown of current psychedelics legislation and reform. As of November 2023, psychedelics are fully illegal in 18 states, though there still may be religious or medical exemptions depending on the drug in question. Legislation reform and decriminalization efforts are ongoing.

Could this pseudo-psychedelic VR experience decrease symptoms of depression?

Researchers report that virtual reality and psychedelics may be leave users with similar insights and therapeutic benefits. Try out this free psychedelic virtual reality experience to see if this holds true for you. According to the program’s creators, a study into the efficacy of this 45-minute experience indicates it may help alleviate symptoms of mild to moderate depression.

How four types of psychedelics affect the brain

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

Veterans reported single dose of ibogaine improved TBI, PTSD, anxiety, and depression

Research published in 2024 on the Central African plant-derived drug included 30 male combat vets who received ibogaine treatment in Mexico. It reported significant reductions in multiple mental health conditions and no serious side effects. Other work, however, has shown the substance can cause fatal cardiac arrhythmias, killing at least 19 people between 1990 and 2008. (Some users may encounter a paywall.)

What can psychedelics teach us about dying?

Psychedelics have made their way into the world of licensed mental healthcare, and the drugs have been proven to help people process and lessen anxiety and depression. What does this mean for people with terminal illnesses who are afraid of death?

How can octopuses and MDMA help scientists understand the human brain?

Research shows that psychedelics may induce something called "critical periods" in the adult brain, which can make our brains more open to learning and changing, like they once were back in early childhood. Psychedelics similarly change how social creatures like octopuses behave, which demonstrates that these animals could help us better understand our own neurobiology.

An overview of modern clinical research on LSD

Researchers have determined that LSD, taken in a medical setting, decreases anxiety related to "life-threatening disease," reduces brain reactivity to fearful faces, increases the meaning and emotional response derived from music, and more. No complications of LSD administration have been observed in medical settings, though acute adverse effects, including exhaustion, nausea, and difficulty concentrating.

People with schizophrenia are excluded from psychedelic research

Individuals with this mental health condition are routinely eliminated from any psychedelic research due to concerns about triggering or worsening psychosis. Yet there is little high-quality research in this area, raising questions about if further research into this question is warranted as interest grows in using psychedelics for therapeutic purposes.

LSD fueled a countercultural movement before evolving into a potential therapeutic

As the use of recreational psychedelics became common, authorities were quick to claim LSD had lasting adverse effects, criminalizing the drug and halting scientific study for decades. Over time, LSD's reputation shifted from a potential source of enlightenment to a dangerous drug that could dim a person's future, and back to a possible therapeutic compound.

The 'definitive' history of magic mushrooms

Where did magic mushrooms come from, and how did they get their magical reputation? This article explains the history of the psychedelic fungi from pre-history to now. The earliest concrete evidence of psychedelic mushroom use is 12,000-year-old murals in Northern Australia that portray mushroom iconography. Considering how many species seek out and consume psychoactive substances, such as Siberian reindeer, it's possible human use of these psychedelic mushrooms may predate these murals.

How psychedelics can potentially reinvent learning

Critical periods, discovered in the early 20th century, describe a period when someone is incredibly sensitive to their environment, and any information learned can stick with them for life. Some researchers argue these states can be "reopened" via psychedelics, which put the mind into a malleable state that can potentially be used to treat conditions ranging from lazy eyes to PTSD.

Mixed reality technologies may help treat depression

A study led by a team from Stanford University showed that MR can help people with depression by providing pathways to engage in activities such as digital board games and dancing. Participants saw reduced symptoms of depression that made their overall treatment plans more successful.

The neurobiology of meaningfulness: the benefits of psychedelics

Psychedelics produce powerful emotions in its users, including a profound sense of meaningfulness. The philosopher William James called this sense "noetic" in the late 19th century, but for decades researchers avoided studying the effects of such drugs on the brain. However, the recent resurgence in psychedelic research has heightened interest in the relationship between this noetic sense resulting from the therapeutic use of drugs. Learn what researchers have found out here.

How to avoid a 'bad trip' advice includes relaxing your mind if you experience scary things and not fighting the feeling

In this video, Michael Pollan, author of "This Is Your Mind On Plants," underscores the gaps in existing understanding about the substances and recommends only taking guided experiences, for safety and help. He tackles how psychedelics work, explains microdosing and psychedelic risks, how the substances could be used to treat addiction, and the history of psychedelic stigma.

JJ Schildkraut theorized depression is linked to brain chemical imbalances—in 1965

Schildkraut was one of the first to put forward this idea, which stemmed from lab animal research. A decade later, researchers published the first landmark paper on fluoxetine—better known by trade name Prozac—which increases serotonin levels in the brain.

Ibogaine is being investigated for treating mental health issues and substance abuse

This compound, which is illegal to use in the US, has had promising results for patients who have tried it in other countries for substance abuse and mental health concerns. This psychoactive substance is not without risks, however; this TED talk points out it's also caused fatal cardiac arrhythmias and shouldn't be taken without medical supervision.

This is the human brain on the world's strongest psychedelic

Within seconds of inhaling a high dose of vaporized synthetic 5-MeO-DMT—a lab-produced substance that otherwise is naturally derived from the glands of the Colorado River toad—it induced slow brain waves. Such waves are typically associated with unconsciousness due to a coma or anesthesia, perhaps explaining why users describe feeling like everything falls away. The compound is currently in clinical trials for treating depression.

See how antidepressants—used by roughly 1 in 10 Americans—were discovered.

Psychedelics set off a flurry of brain activity that may permanently alter it

The brain seems to experience a sharp increase in communication between areas that generally don't interact. New research suggests a thin, sheet-like gray matter structure tucked deep within the brain, between the insular cortex and striatum, may be the key to this change. The area is centrally located and home to many of the receptors that psychedelics target, potentially rewiring the brain and rewriting thought patterns.

Merck developed MDMA in the early 1900s as part of its effort to create a blood clotting drug

The company's chemists were attempting to synthesize a substance that could compete with an existing patent for the best clot medicine of that time, hydrastinine. MDMA was the byproduct of that effort.